Work Area: Private Antitrust Litigation

Mastercard has failed to demonstrate its anticompetitive European interchange fees did not act as a “starting point” in negotiations between banks to set UK rates, counsel to Walter Merricks has argued to the country’s specialist competition tribunal.

27 July 2023

Litigation funders in UK collective antitrust claims have suffered a setback as the country’s highest court ruled in a landmark majority judgment that most funding agreements for competition class actions could be unenforceable.

26 July 2023

Hausfeld has launched a £500 million damages claim against Apple and Amazon, accusing the companies of unlawfully colluding to overcharge millions of UK customers for Apple products sold on Amazon’s marketplace platform.

26 July 2023

ClubReady has illegally monopolised the US market for software used to manage boutique fitness studios through exclusive dealing, mergers and no-poach agreements, a potential rival has said.

26 July 2023

Road Haulage Association can proceed with its certified opt-in class action against members of the EU trucks cartel, a UK appellate court has said - rejecting a rival claimant’s bid to overturn the dismissal of its own opt-out claim.

25 July 2023

A competition expert has filed another class action alleging that Apple abused its dominance by charging developers an “excessive” 30% commission fee before the UK's Competition Appeal Tribunal.

25 July 2023

EssilorLuxottica orchestrates an industry-wide price-fixing conspiracy for eyeglasses through its exclusive contracts to sell and set prices for rival’s products, a putative class action has alleged.

25 July 2023

A roofing supply broker has withdrawn its follow-on damages claim against two of the UK’s largest suppliers of rolled lead, whose two-year price-fixing and market-sharing cartel forced it into bankruptcy in 2017.

24 July 2023

A group of wholesalers can pursue allegations that an energy drink manufacturer violated the Robinson-Patman Act by providing Costco with unfair discounts, a divided panel on the US Court of Appeals for the Ninth Circuit has ruled.

24 July 2023

Earlier this month, a federal jury in San Francisco absolved Gilead Sciences and Teva Pharmaceuticals of allegations they entered into an illegal pay-for delay settlement related to a pair of HIV treatments. GCR USA spoke to Kirkland & Ellis partner Devora Allon, co-lead counsel to Gilead, on how the drugmaker escaped the potential of facing billions in damages.

18 July 2023